WEKO3
アイテム
Antiviral immune response against HTLV-1 invalidates T-SPOT.TB® results in patients with HTLV-1-positive rheumatic diseases
http://hdl.handle.net/10458/0002001529
http://hdl.handle.net/10458/0002001529cf4c76ed-e4e3-474a-8dd8-1b4b91f88758
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
fulltext (2 MB)
|
.png)
|
| アイテムタイプ | 学術雑誌論文 / Journal Article(1) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2025-07-29 | |||||||||||||||||||||||
| タイトル | ||||||||||||||||||||||||
| タイトル | Antiviral immune response against HTLV-1 invalidates T-SPOT.TB® results in patients with HTLV-1-positive rheumatic diseases | |||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 言語 | ||||||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| キーワード | HTLV-1 | |||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| キーワード | IFN-g-releasing assay | |||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| キーワード | rheumatic disease | |||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| キーワード | latent tuberculosis infection | |||||||||||||||||||||||
| キーワード | ||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| キーワード | cytotoxic T lymphocytes | |||||||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||||||||
| アクセス権 | ||||||||||||||||||||||||
| アクセス権 | open access | |||||||||||||||||||||||
| 著者 |
木村, 賢俊
× 木村, 賢俊× 梅北, 邦彦
WEKO
21827
× Iwao, Chihiro
× Kawano, Katsumi
× 橋倉, 悠輝× Hashiba, Yayoi
× Hidaka, Toshihiko
× Sugata, Kenji
× Satou, Yorifumi
× 宮崎, 泰可 |
|||||||||||||||||||||||
| 抄録 | ||||||||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||||||||
| 内容記述 | Background: T-SPOT.TB®, one of the screening tests for latent tuberculosis infection (LTBI), yields invalid results in human T-cell leukemia virus type 1 (HTLV-1)-positive patients with rheumatoid arthritis. However, the detailed mechanisms behind this invalidation are unclear. Additionally, it remains unclear whether T-SPOT.TB® or QuantiFERON-TB (QFT) is more useful in HTLV-1-positive patients with rheumatic disease (RD). Method: Among all of the HTLV-1-positive RD patients who visited our department between August 2012 and December 2022, 44 patients who were screened using T-SPOT.TB® were included in the analysis. QFT testing was performed in 33 of the 44 patients, and the results were compared with that of T-SPOT.TB®. Furthermore, we performed a culture experiment mimicking T-SPOT.TB® using peripheral blood mononuclear cells (PBMCs) obtained from HTLV-1-positive patients with RD. Additionally, T-cell subsets with autonomous product IFN-γ were analyzed using a flow cytometer. Results: Of the included patients, 13 (29.5%) were invalid for T-SPOT.TB® because of the increased number of negative control spots. The median HTLV-1 proviral load in the invalid group was higher than that in the valid group (2.45 vs. 0.49 copies/100 PBMCs, respectively, p = 0.002). QFT was performed in all 33 patients, including 13 patients who were invalid in T-SPOT.TB®. The main source of IFN-γ production was CD8+ T-cells in the T-SPOT.TB® mimic experiment. Furthermore, Tax-expressing CD4+ T-cells and Tax-specific cytotoxic CD8+ T-cells were more frequently observed in patients with invalid results than in patients with valid results. CD4+ T-cell depletion in the T-SPOT.TB® mimic experiment reduced the population of IFN-γ producing CD8+ T cells. Conclusion: T-SPOT.TB® may be invalidated by the interaction between Tax-expressing CD4+ T-cells and cytotoxic CD8+ T-cells. Moreover, HTLV-1-associated immune reactions due to contact between these cells may be unlikely to occur in QFT using whole blood. Therefore, our results reveal the superiority of QFT over T-SPOT.TB® as a screening test for LTBI in HTLV-1-positive patients with RD. |
|||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 内容記述 | ||||||||||||||||||||||||
| 内容記述タイプ | Other | |||||||||||||||||||||||
| 内容記述 | Citation: Kimura M, Umekita K, Iwao C, Kawano K, Hashikura Y, Hashiba Y, Hidaka T, Sugata K, Satou Y and Miyazaki T (2024) Antiviral immune response against HTLV-1 invalidates T-SPOT.TB® results in patients with HTLV-1- positive rheumatic diseases. Front. Immunol. 15:1480506. doi: 10.3389/fimmu.2024.1480506 |
|||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 書誌情報 |
en : Frontiers in Immunology 巻 15 |
|||||||||||||||||||||||
| 出版者 | ||||||||||||||||||||||||
| 出版者 | Frontiers | |||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| DOI | ||||||||||||||||||||||||
| 関連タイプ | isVersionOf | |||||||||||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||||||||||
| 関連識別子 | https://doi.org/10.3389/fimmu.2024.1480506 | |||||||||||||||||||||||
| 権利 | ||||||||||||||||||||||||
| 権利情報 | © 2024 Kimura, Umekita, Iwao, Kawano, Hashikura, Hashiba, Hidaka, Sugata, Satou and Miyazaki. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. | |||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||
| 著者版フラグ | ||||||||||||||||||||||||
| 出版タイプ | VoR | |||||||||||||||||||||||
